Hologic, Inc. (NASDAQ:HOLX) Insider Brandon Schnittker Sells 476 Shares

Hologic, Inc. (NASDAQ:HOLX) insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Hologic Stock Performance

HOLX opened at $83.64 on Friday. The stock has a market cap of $19.52 billion, a PE ratio of 42.67, a P/E/G ratio of 2.64 and a beta of 0.99. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $84.67. The stock’s 50 day simple moving average is $76.29 and its 200-day simple moving average is $75.65. The company has a current ratio of 3.99, a quick ratio of 3.29 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the firm earned $0.93 EPS. Hologic’s quarterly revenue was up 2.7% on a year-over-year basis. Sell-side analysts forecast that Hologic, Inc. will post 4.08 EPS for the current year.

Hedge Funds Weigh In On Hologic

Several institutional investors have recently added to or reduced their stakes in the company. Massmutual Trust Co. FSB ADV increased its holdings in shares of Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 137 shares in the last quarter. Graypoint LLC increased its holdings in Hologic by 3.9% during the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after purchasing an additional 147 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in Hologic by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after purchasing an additional 165 shares during the last quarter. Lincoln National Corp boosted its stake in Hologic by 4.0% in the fourth quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock worth $334,000 after purchasing an additional 178 shares in the last quarter. Finally, Allworth Financial LP increased its stake in shares of Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 179 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on HOLX. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. upped their target price on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.